126 results on '"Messa E"'
Search Results
2. El efecto de una intervención educativa de fisioterapia en la actividad física de adolescentes y adultos jóvenes con lupus eritematoso sistémico
3. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations
4. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia
5. A young man with persistent eosinophilia
6. The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
7. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between the NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations
8. Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
9. P087 Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients
10. P050 Deferasirox is the only iron chelator inducing NF-kB inhibition in myelodysplastic patients and in leukemic cell lines and acts independently from reactive oxygen species reduction
11. Retraction Note: Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between the NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations
12. Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study
13. O que família de crianças com deficiência tem a nos dizer sobre a inclusão escolar de seus filhos?
14. Core binding factor acute myeloid leukemia and c-kit mutations
15. A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping
16. The re-Activation of FoxO3 transcription factor in acute myeloid leukaemia is responsible of the induction of a quiescent status of leukaemic progenitor cells
17. FOXO TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING
18. Deferasiroxtreatment improved the hemoglobin level and decreased transfusion requirements infour patients with the myelodysplastic syndrome and primary myelofibrosis
19. L'ambivalenza in gravidanza in un campione di future madri di gemelli
20. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant kit positive acute myeloid leukemia. Results of an italian multicentric phase II study
21. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia.Results of an Italian Multicentric Phase II Study
22. 93 - Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study
23. I recettori ad attività tirosin kinasica EPHA3 come bersagli terapeutici nelle sindormi mieloproliferative croniche
24. Gene expression analysis based on real time PCR of 95 genes coding for tyrosine kinases in Ph negative chronic myeloproliferative disorders
25. The inhibition of IKK kinase induces growth arrest and apoptosis in AML blast cells
26. universal markers of minimal residual disease
27. THE INHIBITION OF IKK KINASE IS ABLE TO INDUCE GROWTH ARREST AND APOPTOSIS IN AML BLAST CELLS
28. The unbalanced ratio between KTS- and KTS+ isoforms of WT1 may probably be responsible for the dysfunction of its physiological role in leukemic cells
29. Over-expression of the p65 subunit of NF-kB and increased NF-kB binding activity is a common event both in Philadelphia positive and negative Chronic Myeloproliferative Disorders
30. SODIUM VALPROATE ENHANCES IMATINIB INDUCED APOPTOSIS AND GROWTH ARREST IN BCR-ABL CELL LINES
31. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia
32. Myelodysplastic syndromes
33. Down-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias [9]
34. The quantitaive assessment of WT1 gene expression as a method to predict response to STI571 therapy in CML patients
35. NF-kB is involved in the modulation of the Wilms tumor gene
36. Wilms’ tumour gene (WT1) is modulated by NF-kB transcriptional factor
37. O-020 Erythropoietin alpha therapy in 1110 lower-risk MDS patients: A real life survey from the network of regional Italian MDS Registries
38. Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
39. Correction: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity
40. Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity
41. Identification of a Novel Mutation in the L Ferritin Iron-Responsive Element Causing Hereditary Hyperferritinemia-Cataract Syndrome
42. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
43. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.
44. P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register
45. P052 Detection of humoral immune responses against Wilms tumor gene (WT1) product in patients affected by myelodysplastic syndromes
46. P137 Response to erythropoietin (EPO) with or without differentiating treatment with 13-cis-retinoic-acid and dihydroxylated vitamin D3 in myelodysplastic syndromes (MDS)
47. P036 The oral iron chelator ICL670 is a potent inhibitor of NF-kB and this activity is independent from iron overload in MDS cells
48. The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
49. Correction: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity
50. Cerebellar syndrome in lithium poisoning: a case of partial recovery.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.